Top vulvovaginal articles of the year

Risks for recurrent VVC caused by non-albicans candida vs candida albicans

Women with non-albicans Candida (NAC) vulvovaginal candidiasis (VVC) were nearly twice as likely to have multiple physician visits for recurring infections compared to women who had C. albicans (CA) VVC, according to a retrospective chart review in the Journal of Women’s Health.

Oral probiotics to prevent vulvovaginal infections in pregnant women

An oral probiotic formula for the secondary prevention of vulvovaginal infections in pregnant women neither colonized in the vagina nor reduced the rate of repeated vulvovaginal infection, according to a study in the American Journal of Gynecology & Obstetrics.

Microbial interplay of recurrent vulvovaginal candidiasis pathobiology

A clinical study has confirmed that the pathophysiology of recurrent vulvovaginal candidiasis (RVVC) relies primarily on Candida albicans (C. albicans)-specific attributes like hyphal morphogenesis, biofilm formation and pathogenesis that differentiate it from other prominent non-albicans C. (NAC) species.

Study: Risk of BV, VVC increase with young age, limited education, and low income

The incidences of vulvovaginal candidiasis (VVC) and bacterial vaginosis (BV) are especially high in young women, and women with a limited education and low-family income, according to a nationwide cohort study in the International Journal of Infectious Diseases.

Study shows risk of BV, VVC increase with young age, limited education and low income

The incidences of vulvovaginal candidiasis (VVC) and bacterial vaginosis (BV) are especially high in young women, and women with a limited education and low-family income, according to a nationwide cohort study in the International Journal of Infectious Diseases.

Oral ibrexafungerp for treating acute VVC

Patients with acute vulvovaginal candidiasis (VVC) greatly benefited from oral ibrexafungerp (Brexafemme, Scynexis), according to results of a global phase 3 randomized, double-blind, placebo-controlled superiority study published in the international journal of obstetrics and gynecology, BJOG.

Vaginal microbiome of vulvovaginal candidiasis

The VMB may be a biological barrier to pathogenic microorganisms. There is also an increased risk of acquiring various vaginal pathogens when the dominant lactobacilli community is disrupted.

Genital hygiene and infections

Women with bacterial vaginosis (BV) and/or vulvovaginal candidiasis (VVC) were significantly less likely to use intimate soap and moist wipes after urination compared to healthy women without any vulvovaginal symptoms, according to a cross-sectional study published in the journal Revista Brasileira de Ginecologia e Obstetricia.

Vulvodynia not associated with vulvovaginal candidiasis

Not only does vulvodynia impact a woman’s sexual and psychological health, but it also places significant financial burden on those seeking treatment.

Berberine promising therapy to treat vulvovaginal candidiasis

Vaginal yeast infections were successfully treated with berberine, a biologically active herbal alkaloid, according to a study published in Frontiers in Pharmacology.

Drug treatments show microbiome changes in women with mixed vaginitis

A study published in Frontiers in Cellular and Infection Microbiology observed significant vaginal microbiome alterations in patients with bacterial vaginosis (BV) plus vulvovaginal candidiasis (VVC) mixed vaginitis before and after drug treatment.

Host immune responses in recurrent vulvovaginal candidiasis

A study published in Frontiers in Immunology indicates that for the prognosis of recurrent vulvovaginal candidiasis (RVVC) and vulvovaginal candidiasis (VVC), the host-immune responses, particularly Th1/2 immunity, may play a vital role.

Eugenol to treat Candida species infection

The compound may also provide a synergistic effect in combination with fluconazole.

The future of ibrexafungerp for prevention of recurrent yeast infections

Nkechi Azie, MD, MBA, FIDSA, vice president of clinical development and medical affairs at SCYNEXIS, discusses the potential FDA approval of ibrexafungerp (Brexafemme; SCYNEXIS) for the prevention of recurrent vulvovaginal candidiasis.

Bacterial vaginosis during pregnancy may heighten risk of preterm birth, pregnancy loss

Bacterial vaginosis during pregnancy may lead to increased risks for preterm birth, preterm delivery, and spontaneous abortion, according to new research in the Archives of Gynecology and Obstetrics.

Dare Bioscience announces grant to develop vaginal thermosetting gel for delivery of live biotherapeutics

Daré Bioscience announced yesterday that it has received a grant from the Bill & Melinda Gates Foundation of $584,986 to support its efforts related to the development of a vaginal thermosetting gel formulation for the delivery of live biotherapeutics that can be reconstituted at the point of care.

Bacterial vaginosis during pregnancy may heighten risk of preterm birth, pregnancy loss

Bacterial vaginosis during pregnancy may lead to increased risks for preterm birth, preterm delivery, and spontaneous abortion, according to new research in the Archives of Gynecology and Obstetrics.

Dare Bioscience announces grant to develop vaginal thermosetting gel for delivery of live biotherapeutics

Daré Bioscience announced yesterday that it has received a grant from the Bill & Melinda Gates Foundation of $584,986 to support its efforts related to the development of a vaginal thermosetting gel formulation for the delivery of live biotherapeutics that can be reconstituted at the point of care.